NASDAQ
BHST
Last Price
US $2.79
Valuation
Financial
Performance
Financial risk - Cash flow debt coverage.
BioHarvest Sciences Inc. Common Stock cash flow to debt ratio of -51.23% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.
Financial risk - Healthy cash flow growth.
BioHarvest Sciences Inc. Common Stock's free cash flow has decreased 0.65% from $-9.52M last year to $-9.58M, signaling decreasing performance
Financial risk - Healthy debt to equity ratio.
BioHarvest Sciences Inc. Common Stock's debt to equity ratio is 0.71, which means that the company's assets are unhealthy financed, signaling financial risk. READ MORE: A ratio over 0.60 means the company finances its assets with debt, signaling financial risk. If ratio is negative, the company spent its own equity and risks bankruptcy
Financial stability - Healthy debt to equity ratio development.
BioHarvest Sciences Inc. Common Stock's debt has decreased relative to shareholder equity from 10.39 last year to 0.71 today, signaling strengthened financials
Financial risk - Net debt/EBITDA.
BioHarvest Sciences Inc. Common Stock has negative EBITDA, making leverage ratio unreliable
Financial risk - ICR.
BioHarvest Sciences Inc. Common Stock's interest coverage ratio is -0.91, which means that the company struggles to meet interest obligations, signaling financial risk.
Financial stability - Profit margin growth.
BioHarvest Sciences Inc. Common Stock's profit margin has increased (-36.54%) in the last year from -51.27% to -32.54%, signaling increasing performance
Financial stability - Short term assets vs short term liabilities.
BioHarvest Sciences Inc. Common Stock's short-term assets of $30.50M exceed its short-term liabilities of $7.68M
Decreasing performance - ROA.
BioHarvest Sciences Inc. Common Stock's return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization
Decreasing performance - Absolute return on equity.
BioHarvest Sciences Inc. Common Stock's return on equity of -88.01%, is lower than 15.00%, indicating bad performance
Decreasing performance - Earnings quality.
BioHarvest Sciences Inc. Common Stock's operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation
Decreasing performance - Earnings stability.
BioHarvest Sciences Inc. Common Stock had positive net income in only 0.00 out of 5 years, indicating unstable earnings
Decreasing performance - Free cash flow.
BioHarvest Sciences Inc. Common Stock has negative free cash flow, indicating the company is burning cash rather than generating it
Decreasing performance - FCF yield.
BioHarvest Sciences Inc. Common Stock has negative free cash flow, indicating cash burn
Increasing performance - Healthy earnings growth.
BioHarvest Sciences Inc. Common Stock's yearly earnings has increased -13.77% since last year from $-12.91M to $-11.13M, signaling increasing performance
Increasing performance - Healthy revenue growth.
BioHarvest Sciences Inc. Common Stock's yearly revenue has increased 37.00% since last year from $25.19M to $34.51M, signaling increasing performance
Decreasing performance - ROIC.
ROIC -14.43% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.
Increasing performance - 3-year revenue CAGR.
BioHarvest Sciences Inc. Common Stock's 3-year revenue CAGR of 84.46% is positive, indicating growing revenue over the past 3 years
Increasing performance - Revenue consistency.
BioHarvest Sciences Inc. Common Stock had revenue growth in 5.00 out of 5 years, indicating consistent revenue performance
Decreasing performance - ROE consistency.
BioHarvest Sciences Inc. Common Stock had positive ROE in only 0.00 out of 5 years, indicating inconsistent returns on equity
Overvalued - DCF valuation.
BioHarvest Sciences Inc. Common Stock has insufficient data to evaluate this check.
Overvalued - Earnings yield.
BioHarvest Sciences Inc. Common Stock has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails
Overvalued - EBITDA valuation.
BioHarvest Sciences Inc. Common Stock is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model
Overvalued - EV/EBITDA.
BioHarvest Sciences Inc. Common Stock has negative or missing EBITDA, making EV/EBITDA ratio unreliable
Overvalued - PEG ratio value.
BioHarvest Sciences Inc. Common Stock has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails
Undervalued - P/B ratio.
BioHarvest Sciences Inc. Common Stock has a price-to-book ratio of 2.75x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value
Undervalued - P/S ratio.
BioHarvest Sciences Inc. Common Stock has a price-to-sales ratio of 1.80x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue
Profit margin
Current Ratio
Capital Returns
-88.01%
Return on equity
ROIC: -14.43%
Valuation History
-4.5X
Price to Earnings
EV/EBITDA: -6.8X
Cash flow
Profit margin
-2.97%
(FY vs FY)
Cash flow Y/Y
-15.83%
(FY vs FY)
Fair Value
Market $2.79
—
Default assumptions
Base valuations use default assumptions. Customize in the Valuator.